Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tremelimumab - MedImmune

Drug Profile

Tremelimumab - MedImmune

Alternative Names: Anti CTLA 4 monoclonal antibody-Pfizer; CP-675; CP-675206; Ticilimumab

Latest Information Update: 05 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AIO Studien gGmbH; Amgen; ARCAGY/GINECO Group; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Charite - Universitatsmedizin Berlin; Dana-Farber Cancer Institute; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Hoosier Cancer Research Network; Immunocore; Institute Gustave-Roussy; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Pfizer; Seoul National University Hospital; UNICANCER; University College London; University of Maryland Greenbaum Cancer Center; Yonsei University College of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal cancer; Germ cell and embryonal neoplasms; Glioblastoma; Lung cancer; Neuroendocrine tumours; Oesophageal cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma; Thyroid cancer
  • Phase I/II Haematological malignancies; Malignant melanoma
  • Phase I Cervical cancer; Diffuse large B cell lymphoma; Gynaecological cancer; Myelodysplastic syndromes; Vulvovaginal cancer

Most Recent Events

  • 28 Oct 2019 Efficacy data and adverse events data from a phase III POSEIDON trial in non-small cell lung cancer released by AstraZeneca
  • 29 Aug 2019 AstraZeneca plans a phase Ib trial for Bladder cancer (Combination therapy, Late-stage disease) in USA (NCT04073160)
  • 29 Jul 2019 National Cancer Institute plans a phase II trial for Ovarian Cancer (Recurrent, Combination therapy, Second line therapy or greater) in October 2019 (NCT04034927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top